Translate

Search This Blog

Search Tool




Jan 3, 2019

Bristol-Myers to buy Celgene in a $74 billion deal.

Berkeley Lovelace Jr.



Top Stories
Top Stories
Biotech and Pharma
|
Bristol-Myers Squibb on Thursday announced plans to buy Celgene in a cash and stock deal the company valued at $74 billion.
Under the agreement, Celgene shareholders will receive 1 Bristol-Myers Squibb share and $50 in cash for each share of Celgene.
The boards of directors of both companies approved the deal.
This story is developing. Please check back for updates.

No comments:

Post a Comment